DURHAM, N.C. (AP) — DURHAM, N.C. (AP) — BioCryst Pharmaceuticals Inc. (BCRX) on Monday reported a loss of $14 million in its third quarter.

The Durham, North Carolina-based company said it had a loss of 7 cents per share.

The results matched Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was also for a loss of 7 cents per share.

The drugmaker posted revenue of $117.1 million in the period, surpassing Street forecasts. Three analysts surveyed by Zacks expected $114.8 million.

BioCryst expects full-year revenue in the range of $443 million to $448 million.

BioCryst shares have risen 41% since the beginning of the year. The stock has climbed 49% in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BCRX at https://www.zacks.com/ap/BCRX